Octreotide therapy in patients with a left ventricular assist device and bleeding gastrointestinal angiodysplasias.

Ahmed Ibrahim, Jad Allam, Don C Rockey
{"title":"Octreotide therapy in patients with a left ventricular assist device and bleeding gastrointestinal angiodysplasias.","authors":"Ahmed Ibrahim, Jad Allam, Don C Rockey","doi":"10.1016/j.amjms.2025.03.008","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Angiodysplasias commonly develop in patients with left ventricular assist devices (LVADs) and often bleed recurrently. Whether octreotide reduces the burden of angiodysplasia or the frequency of bleeding in these patients is controversial. Hence, we aimed to study the effect of long-acting octreotide on angiodysplasia bleeding in LVAD patients.</p><p><strong>Methods: </strong>Between May 2012 and December 2023, 65 patients with LVAD and angiodysplasia were identified at our tertiary care medical center. Of those, 33 patients received octreotide therapy. Complete clinical data were abstracted from the medical record, and outcomes pre and post octreotide therapy were examined.</p><p><strong>Results: </strong>In 33 patients (61±8 years old and 9 women) who received long-acting octreotide for recurrent angiodysplasia bleeding that failed to respond to endoscopic therapy, the small intestine was the most common site involved. Prior to octreotide, patients received an average of 2.0±3.0 units/month of PRBCs over an average of 16 months, which decreased to 0.5±0.8 units/month over 31 months on therapy. Over an average period of 31 months on octreotide therapy, GI bleeding events and the number of endoscopic therapies per month decreased from 0.4±0.2 to 0.1±0.2 (p= 0.01) and from 0.7±0.8 to 0.1±0.2 (p= 0.001), respectively. Finally, hemoglobin and hematocrit levels increased over the 31 month follow-up period while on octreotide therapy.</p><p><strong>Conclusion: </strong>In patients with an LVAD and recurrent angiodysplasia bleeding, octreotide appeared to reduce the number of GI bleeding events, the need for GI endoscopic therapies, and the frequency of PRBC transfusions.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American journal of the medical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.amjms.2025.03.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Angiodysplasias commonly develop in patients with left ventricular assist devices (LVADs) and often bleed recurrently. Whether octreotide reduces the burden of angiodysplasia or the frequency of bleeding in these patients is controversial. Hence, we aimed to study the effect of long-acting octreotide on angiodysplasia bleeding in LVAD patients.

Methods: Between May 2012 and December 2023, 65 patients with LVAD and angiodysplasia were identified at our tertiary care medical center. Of those, 33 patients received octreotide therapy. Complete clinical data were abstracted from the medical record, and outcomes pre and post octreotide therapy were examined.

Results: In 33 patients (61±8 years old and 9 women) who received long-acting octreotide for recurrent angiodysplasia bleeding that failed to respond to endoscopic therapy, the small intestine was the most common site involved. Prior to octreotide, patients received an average of 2.0±3.0 units/month of PRBCs over an average of 16 months, which decreased to 0.5±0.8 units/month over 31 months on therapy. Over an average period of 31 months on octreotide therapy, GI bleeding events and the number of endoscopic therapies per month decreased from 0.4±0.2 to 0.1±0.2 (p= 0.01) and from 0.7±0.8 to 0.1±0.2 (p= 0.001), respectively. Finally, hemoglobin and hematocrit levels increased over the 31 month follow-up period while on octreotide therapy.

Conclusion: In patients with an LVAD and recurrent angiodysplasia bleeding, octreotide appeared to reduce the number of GI bleeding events, the need for GI endoscopic therapies, and the frequency of PRBC transfusions.

求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信